California Science Review Panel Approves Study on MDMA Treatment for Autistic Adults
By: Eric W. Dolan
The Raw Story
The Raw Story announces MAPS’ new study into MDMA-assisted therapy for social anxiety in autistic adults that recently received approval from the Research Advisory Panel of California and the Institutional Review Board at Harbor-UCLA Medical Center/Los Angeles Biomedical Research Institute. Researchers will study the therapeutic effects of MDMA-assisted therapy in 12 autistic adults, once the study has final approval from the Drug Enforcement Administration.
Two major committees have approved a study on the use of MDMA to help autistic adults with social anxiety, according to the organization that hopes to conduct the research.
In its most recent newsletter, the Multidisciplinary Association of Psychedelic Studies said the Research Advisory Panel of California and the Institutional Review Board at Harbor-UCLA Medical Center/Los Angeles Biomedical Research Institute have approved the research.
The study will investigate the safety and therapeutic potential of MDMA-assisted therapy for treating social anxiety in 12 autistic adults.
MDMA is known on the street as the club drug ecstasy and molly. The drug has been found to reduce the fear of emotional harm while promoting feelings of social connection.
The researchers still need to obtain permission from the Drug Enforcement Administration before they can conduct the study. MDMA is classified as a Schedule I substance, the most restrictive category of the federal Controlled Substances Act.